Partners:

Cytochroma has partnered with Mitsubishi Tanabe Pharma Corporation (MTPC) to develop and commercialize CTA018 and related follow-up compounds in the U.S. and Asia.

MTPC is a research-driven global pharmaceutical company based in Japan.  It specializes in the fields of cardiovascular and metabolic diseases, brain and nerve diseases, and renal and urinary system diseases. The company was established through the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation in October 2007.  MTPC commits to bring its innovation to patients around the world, and plans to build a commercialization presence in the US.  MTPC is currently developing two Phase III clinical candidates in the US and EU; MP-146 for CKD and MCI-196 for hyperphosphatemia. 

For more information, please visit www.mt-pharma.co.jp